title: Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome.
abstract: This study was performed on 282 patients with primary head and neck squamous cell carcinomas to evaluate the prognostic importance of 11q13 amplification. Amplification of the 11q13 DNA markers, HST-1/FGF-4 and BCL-1, evaluated by Southern and slot blot hybridisation, was detected in 52% of tumours. 11q13 amplification was associated with tumour site since this alteration occurred in 76% of tumours arising in the hypopharynx, versus 40% in the other sites (P = 0.0007). 11q13 amplification was also significantly related to the presence of involved neck lymph nodes (P = 0.013). The relationship between 11q13 amplification and risk of progression was studied in two subgroups of head and neck cancer patients with regard to treatment modalities. The presence of 11q13 amplification in the tumour was not significantly associated with a shorter event-free survival (P = 0.82) and crude survival (P = 0.61) of the 201 patients treated by surgery and postoperative radiotherapy. Similarly, absence of a relationship was observed for the group of 79 patients treated by surgery alone. These results confirm that 11q13 amplification is a prominent event in head and neck squamous cell carcinoma, indicating that it may be a common genetic event in the development of these neoplasms, but is not a reliable prognostic marker.
authors.affiliation: Department of Tumour Biology, Centre Paul Strauss, Strasbourg, France.
authors.forename: D
authors.initials: D
authors.lastname: Muller
authors.forename: R
authors.initials: R
authors.lastname: Millon
authors.forename: M
authors.initials: M
authors.lastname: Velten
authors.forename: G
authors.initials: G
authors.lastname: Bronner
authors.forename: G
authors.initials: G
authors.lastname: Jung
authors.forename: A
authors.initials: A
authors.lastname: Engelmann
authors.forename: H
authors.initials: H
authors.lastname: Flesch
authors.forename: M
authors.initials: M
authors.lastname: Eber
authors.forename: G
authors.initials: G
authors.lastname: Methlin
authors.forename: J
authors.initials: J
authors.lastname: Abecassis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015139:Blotting, Southern; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D002880:Chromosomes, Human, Pair 11; D005260:Female; D051519:Fibroblast Growth Factor 4; D005346:Fibroblast Growth Factors / Q000235:genetics; D005500:Follow-Up Studies; D005784:Gene Amplification; D019940:Genes, bcl-1; D005819:Genetic Markers; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011518:Proto-Oncogene Proteins / Q000235:genetics; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: C496445:FGF4 protein, human; D051519:Fibroblast Growth Factor 4; D005819:Genetic Markers; D011518:Proto-Oncogene Proteins; D005346:Fibroblast Growth Factors